Intracellular EtBr accumulation in Mtb
Cell-based study · Mtb mc26206 [1]
Mtb mc26206 was treated with Norverapamil at 25 μM to assess intracellular EtBr accumulation against a control without drug. Norverapamil inhibited both efflux activities, although less than the other compounds.
| Endpoint | Reported result | Reference |
|---|---|---|
| Percent increase in intracellular EtBr accumulation | Reported result Norverapamil also inhibited both efflux activities albeit less than the other compounds | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 25 μM
- Exposure duration
- until steady state was reached, typically after 90 min
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Norverapamil
The paper names Norverapamil without stating the salt or form; not verified as the hydrochloride form supplied as A12249. No dose conversion or lot validation.
Results > Verapamil’s Inhibition of Mtb Efflux Pumps Is Linked to Its Human P-glycoprotein (PGP) Inhibitory Activity. (S47); Materials and Methods > EtBr Accumulation Assay. (S108, S110); Fig. 3. legend (S164)
Percent increase in intracellular EtBr accumulation: Percent increase in intracellular EtBr accumulation; comparator: without drug present — Results > Verapamil’s Inhibition of Mtb Efflux Pumps Is Linked to Its Human P-glycoprotein (PGP) Inhibitory Activity. (S47); Fig. 3. legend (S164)